Actively Recruiting
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Led by University Health Network, Toronto · Updated on 2025-09-05
75
Participants Needed
1
Research Sites
255 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single centre, interventional, randomized Phase II, two-arm prospective trial investigating if Stereotactic Body Radiotherapy (SBRT) to all sites of Oligopressive (OP) disease while remaining on current Systemic Therapy (ST) will improve biochemical control compared to Standard of Care (SoC) (which involves a change in ST) for patients with OP Castrate Resistance Prostate Cancer (CRPC).
CONDITIONS
Official Title
Stereotactic Body Radiotherapy or Standard of Care for Prostate Oligoprogressive Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age >18 years
- Able to provide informed consent
- Histologic diagnosis of prostate adenocarcinoma
- Castrate Resistance Prostate Cancer
- Radiographic evidence of <10 sites of extra-cranial oligopressive metastatic lesions
- Receiving any line of systemic therapy for >3 months
- All sites of oligopressive disease can be safely treated with SBRT
- ECOG performance status 0-3
You will not qualify if you...
- Evidence of spinal cord compression
- Contraindication to radiotherapy
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Princess Margaret Cancer Center
Toronto, Ontario, Canada, M5G 2M9
Actively Recruiting
Research Team
R
Rachel Glicksman, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here